

Lymphocyte Cytotoxicity of oxLDL in Patients with Atherosclerosis

Mohammad Jafar Mahmoudi¹, Maryam Mahmoudi², Fereydoon Siassi², Fazel Shokri³, Mohammad Reza Eshraghian⁴, Amir Hassan Zarnani⁵, Reza Chahardoli², Mona Hedayat⁶, Jalal Khoshnoodi³, Hashem Nayeri⁷, Nima Rezaei^{6,8}, Ali-Akbar Saboor-Yaraghi^{2*}

¹Division of Cardiology, Department of Internal Medicine, School of Medicine, ²Department of Nutrition and Biochemistry, ³Department of Immunology, ⁴Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, ⁵Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, ⁶Molecular Immunology Research Center, School of Medicine, Tehran University of Medical Sciences, ⁷Falavarjan Islamic Azad University, Falavarjan, Isfahan, ⁸Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran

ABSTRACT

Background: Atherosclerosis, a chronic inflammatory disease of the vessel wall is characterized by local and systemic immune responses to a variety of antigens. Oxidized low-density lipoprotein (oxLDL) is considered as an important determining factor in the pathogenesis of atherosclerosis. **Objective:** The purpose of this study was to investigate the degree of peripheral blood mononuclear cells (PBMC) vulnerability to in vitro oxLDL-induced cytotoxicity from atherosclerotic patients in comparison to healthy individuals. **Methods:** Thirty patients with atherosclerotic lesions, confirmed by angiography, and 30 matched healthy individuals were investigated. PBMC was prepared from individuals' blood samples which were further stimulated with low dose (1 µg/mL) and high dose (50 µg/mL) of extensively oxidized LDL. MTT assay was utilized to measure cell viability and proliferation. Stimulation index (SI) was calculated as mean ratio of optical density (OD) of the stimulated cells divided by OD of untreated cells. **Results:** Low dose oxLDL treatment caused no significant proliferative or cytotoxic effect in the control group; however, similar treatment caused significant cytotoxic effect in the patient group compared to the controls (p=0.026). High dose oxLDL treatment induced more significant cytotoxicity in the patient compared to the control group (p=0.006). Comparison of the SI between the two groups of patients and controls showed significantly lower index by either the low (p=0.03) or the high dose (p<0.001) oxLDL in the patients compared to the controls. **Conclusions:** PBMC from patients with atherosclerosis showed increased susceptibility to oxLDL-induced cytotoxicity. Our results imply that prolonged exposure to elevated levels of circulating oxLDL could weaken the cellular defense mechanisms by progressive depletion of the pool of antiapoptotic proteins, rendering the cells more vulnerable to oxLDL-induced cell death.

Keywords: Atherosclerosis, Cytotoxicity, oxLDL, Peripheral Blood Mononuclear Cells

*Corresponding author: Dr. Ali-akbar Saboor-Yaraghi, Department of Nutrition and Biochemistry, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran, e-mail: asaboor@sina.tums.ac.ir

INTRODUCTION

Atherosclerosis is a chronic inflammatory disease of the vessel walls characterized by involvement of both innate and adaptive immunity in lesion formation and disease progression (1,2). Oxidized low-density lipoproteins (oxLDL), encompassing a variety of oxidatively modified lipids and proteins, are believed to play a central role in atherogenesis (3). OxLDL provokes defective endothelium-mediated vasodilation, induces local chemokine production, endothelial adhesion molecule expression, monocyte recruitment to the arterial wall and subsequent foam cell formation. It also promotes smooth muscle cell migration and proliferation associated with increased extracellular matrix synthesis, and subsequently shifts the haemostatic mechanisms in favor of thrombosis (4).

OxLDL-induced cytotoxicity in a variety of cell types, including monocytes (5), macrophages (6), lymphocytes (7), endothelial cells (8), and vascular smooth muscle cells (9), is potentially involved in necrotic core formation, endothelial cell lining defect and plaque rupture with subsequent thrombus formation (3). The toxic lipid constituents of oxidized lipoproteins, including a variety of oxysterols, have been demonstrated to increase intracellular reactive oxygen species (ROS) generation, induce structural modifications of cell proteins, and alter a variety of proapoptotic signaling pathways and gene expression (10). Oxysterols trigger both mitochondrial (intrinsic) and death receptor-dependent (extrinsic) apoptotic pathways in various cell types; however, the respective roles of individual compounds remain to be elucidated (11,12).

In early atheromatous lesions, increased macrophage apoptosis and efficient clearance of apoptotic cells, a process known as efferocytosis, have been shown to slow the progression of atherosclerosis (13-15), possibly through prevention of post-apoptotic secondary necrosis and induction of transforming growth factor (TGF)- β , IL-10, and other mediators of inflammation resolution (16). In contrast, defective efferocytosis has been demonstrated in advanced atheromatous lesions, which contributes enormously to necrotic core formation and increased plaque vulnerability (17). Several hypotheses have been proposed to account for defective efferocytosis (16), including poor display of efferocytosis ligands on the apoptotic cells, defective expression or function of bridging molecules or efferocytosis receptors, and altered subpopulations of phagocytes (18). In addition, extensive macrophage apoptosis may limit the pool of competent efferocytes and overwhelms the phagocytic capacity of the remaining macrophages (16).

The cytotoxic effect of oxLDL on normal human peripheral blood mononuclear cells (PBMC) has been demonstrated *in vitro* (5,19-21). Given the paucity of similar studies in patients with atherosclerosis, the purpose of the present study was to investigate the degree of PBMC vulnerability to *in vitro* oxLDL-induced cytotoxicity from atherosclerotic patients in comparison to healthy individuals.

MATERIALS AND METHODS

Subjects. Thirty patients (25 male and 5 female; mean age of 53.2 ± 7.8 years, ranging from 40 to 64 years) with diagnosis of coronary artery disease (CAD), who referred to the Division of Cardiology in the teaching hospitals of Tehran University of Medical

Sciences, were enrolled in this study. All these patients had significant atherosclerotic lesions confirmed by angiography, defined as luminal stenosis $\geq 50\%$ in at least one major coronary artery branch. Subjects with active infections or autoimmune diseases were excluded from the study. Thirty healthy sex- (25 male and 5 female) and age-matched (mean age of 51.0 ± 6.8 years, ranging from 40 to 62 years) individuals with no history of CAD were also enrolled. The study was approved by the Ethics Committee of Tehran University of Medical Sciences and Health Services. Written informed consent was obtained from all subjects prior to blood collection.

Cell preparation. 10 mL of fasting venous blood sample was drawn from all subjects and collected in sodium citrate tubes. Prior to PBMC separation, the blood was centrifuged at $400 \times g$ for 10 minutes at room temperature to remove the plasma, and sufficient quantity of sterile phosphate-buffered saline (PBS) was added to bring the blood to its original volume. Subsequently, the blood was diluted with an equal volume of PBS and was carefully layered onto half the volume of Ficoll-Histoprep (BAG Health Care GmbH, Germany), using plastic pipettes. Centrifugation was carried out at $800 \times g$ for 30 minutes at room temperature. The layer of mononuclear cells at the interface was removed using a sterile disposable Pasteur pipette, diluted with PBS, and centrifuged at $250 \times g$ for 10 minutes at room temperature. The washing step was repeated twice. Cell viability and cell counts were assessed by Trypan blue exclusion method. Mononuclear cells were resuspended in culture medium (RPMI-1640 supplemented with 10% heat inactivated fetal calf serum; Gibco, Invitrogen, UK), diluted to 1×10^6 cells per mL, and plated on 96-well flat-bottomed microtiter plates at a density of 1.5×10^5 cells per well. Cultured cells were stimulated with a low dose ($1 \mu\text{g/mL}$) and a high dose ($50 \mu\text{g/mL}$) of extensively oxidized LDL and incubated at 37°C under a 5% CO_2 environment for 66 hours.

Preparation of oxidized LDL. $500 \mu\text{g/mL}$ ($100 \mu\text{g/mL}$ protein) of low density lipoprotein (LDL; Sigma, USA) was incubated with $10 \mu\text{M}$ copper sulfate (CuSO_4 ; Aldrich, USA) overnight at 37°C in order to prepare extensively oxidized LDL (22). Oxidation was continuously monitored by measuring the kinetics of conjugated diene formation at 234 nm over a period of 8 hours (23). Oxidation reaction was terminated by cooling and addition of ethylenediaminetetraacetic acid (EDTA). The degree of LDL oxidation was determined by measuring thiobarbituric acid reactive substances (TBARS) (24). Exposure of LDL to $10 \mu\text{M}$ CuSO_4 resulted in an increase in the amount of TBARS in the LDL preparation from 2.1 to 42 nano mole MDA eq/mg LDL protein. OxLDL preparation was kept in $2-8^\circ\text{C}$ and used within one week.

Colorimetric MTT assay. In order to determine cell proliferation and cytotoxicity, the number of metabolically active cells was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (25). Following the incubation period of 66 hours, 0.5 mg/mL MTT dye was added and the plates were incubated at 37°C under a 5% CO_2 environment for 4 hours. The formazan water insoluble precipitate was extracted and dissolved in $200 \mu\text{L}$ dimethyl sulfoxide (DMSO). Subsequently, the absorbance (optical density, OD) was determined at 550 nm using micro ELISA plate reader (ELX 800, BioTek, USA). Stimulation index (SI) was calculated as the mean ratio of the OD of the stimulated cells divided by that of the non-stimulated cells.

Statistical analysis. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) software, version 16.0. Comparisons of OD between untreated and stimulated cells were made using paired-samples t-test. Comparisons of

the results between two groups of patients and controls were done using independent samples t-test. P value of less than 0.05 was considered statistically significant.

RESULTS

Stimulation with low dose oxLDL. Although stimulation of PBMC with low dose oxLDL did not cause any significant proliferative or cytotoxic effect in the control group (0.82 ± 0.14 vs. 0.84 ± 0.16 , $p=0.45$), similar treatment caused significant cytotoxic effect on the PBMC of the patient group (0.91 ± 0.16 vs. 0.87 ± 0.17 , ($p=0.026$) (Figure 1). Comparison of SI between patients and controls revealed a significantly lower index in the patient group ($p=0.03$, Table 1).

Table 1. Comparison of the stimulation index after stimulating the mononuclear cells with different doses of the stimulation.

Stimulant	Stimulation index		P value
	Patients	Controls	
Low dose oxLDL	0.95 ± 0.14	1.04 ± 0.19	0.032
High dose oxLDL	0.63 ± 0.16	0.85 ± 0.20	<0.001
P value	<0.001	<0.001	<0.001

Stimulation with high dose oxLDL. Increased cytotoxicity was found when the cells were treated with a high dose of oxLDL ($p<0.001$) in both the patients and the controls (Figure 1).




Figure 1. Comparison of optical density (OD) between unstimulated and stimulated cells treated with either the low or high dose of oxLDL in both the patients and controls.

After stimulating with a high dose of oxLDL, the mean OD was 0.57 ± 0.14 in the patient group, which was significantly lower than the value of 0.69 ± 0.18 observed in the control group ($p=0.006$). The high dose of oxLDL caused a significantly more cytotoxicity, and therefore decreased the SI in the patient group ($p<0.001$, Table 1). Comparison of the stimulation with the high and low dose of oxLDL revealed significantly higher inhibitory effect of the high dose of oxLDL in both the patient and control groups ($p<0.001$, Table 1).

DISCUSSION

In the present study, higher cytotoxicity of oxLDL in cultured PBMC from atherosclerotic patients was found compared to the healthy individuals. In response to the low dose of oxLDL, no significant proliferative or cytotoxic effect was detected in the PBMCs obtained from the healthy subjects, whereas a similar treatment caused a significant cytotoxic effect in the patient group. Increased cytotoxicity was detected in cultured cells of both groups treated with the high dose of oxLDL, an effect which was more prominent in the patient group. Over the past decade, oxLDL-induced cell death, including both necrosis and apoptosis, has been demonstrated repeatedly in healthy individuals (5-9,19-21).

OxLDL has been shown to induce apoptosis in unstimulated human monocytes freshly isolated from the peripheral blood of healthy individuals via ROS generation, mitochondrial Bax translocation with mitochondrial membrane potential disruption, cytosolic *cytochrome c* release and subsequent caspase-9 and -3 activation (5). In addition, oxLDL significantly inhibits PBMC proliferative responses to different mitogens, antigens, and human recombinant IL-2 (19,20), which was counterbalanced by the addition of *N*-acetylcysteine, a free radical scavenger and glutathione precursor (19). The results of the present study point to the increased vulnerability of PBMCs from atherosclerotic patients to OxLDL-induced cytotoxicity in vitro. One plausible explanation is that prolonged exposure to elevated levels of circulating oxLDL would down regulate the expression of the antiapoptotic members of the Bcl-2 family of proteins (26-28) and the inhibitor of apoptosis proteins (IAPs) (29,30) in PBMCs from atherosclerotic patients. The latter specifically binds to and inhibits active caspases and is negatively regulated by IAP-binding proteins, including Omi and Smac/DIABLO (31).

It seems that the cellular response induced by oxLDL depends on the degree of oxidation, duration of exposure, and its concentration (6). A 24-hour exposure to 100 $\mu\text{g/mL}$ of the lightly oxidized LDL induced macrophage activation and proliferation, whereas at the same concentration, the extensively oxidized LDL induced cell death. In contrast, cells incubated for 4-6 hours showed a proliferative response to 100 $\mu\text{g/mL}$ of the extensively oxidized LDL. Furthermore, 200 $\mu\text{g/mL}$ of oxLDL caused cell death regardless of the degree of oxidation (6). In the present study, cultured PBMC from atherosclerotic patients treated with 1 $\mu\text{g/mL}$ of oxLDL for 66 hours showed increased cell death. Therefore, comparing the results of differently designed in vitro studies using oxidatively modified LDL may not be conclusive due to the variations in the mode and degree of oxidation, dose, and exposure time.

In our study, cultured PBMC from atherosclerotic patients showed increased vulnerability to oxLDL-induced cytotoxicity in comparison to healthy individuals. Hyperlipidemia, ongoing systemic inflammation, and the resultant increase in circulating oxLDL concentration could be hypothetically involved in increased oxLDL-induced cytotoxicity. Although continuous therapy with lipid lowering agents and antioxidants is proven to be beneficial in patients with atherosclerosis, in order to intervene more effectively, further studies to uncover the underlying cellular and molecular mechanisms with potential therapeutic targeting would be of immense value.

ACKNOWLEDGMENTS

This research has been supported by Tehran University of Medical Sciences and Health Services grant (86-04-27-6617). The authors are very grateful for all colleagues in the Department of Nutrition and Biochemistry, School of Public Health, Tehran University of Medical Sciences for their kind helps and advices in the laboratory. We would like to thank all the patients and control subjects for their kind collaboration in this study.

REFERENCES

1. Lundberg AM, Hansson GK. Innate immune signals in atherosclerosis. *Clin Immunol.* 2010; 134:5-24.
2. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. *Clin Immunol.* 2010; 134:33-46.
3. Salvayre R, Auge N, Benoist H, Negre-Salvayre A. Oxidized low-density lipoprotein-induced apoptosis. *Biochim Biophys Acta.* 2002; 1585:213-21.
4. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. *Free Radic Biol Med.* 1996; 20:707-27.
5. Ermak N, Lacour B, Drueke TB, Vicca S. Role of reactive oxygen species and Bax in oxidized low density lipoprotein-induced apoptosis of human monocytes. *Atherosclerosis.* 2008; 200:247-56.
6. Han CY, Pak YK. Oxidation-dependent effects of oxidized LDL: proliferation or cell death. *Exp Mol Med.* 1999; 31:165-73.
7. Alcouffe J, Caspar-Bauguil S, Garcia V, Salvayre R, Thomsen M, Benoist H. Oxidized low density lipoproteins induce apoptosis in PHA-activated peripheral blood mononuclear cells and in the Jurkat T-cell line. *J Lipid Res.* 1999; 40:1200-10.
8. Li D, Mehta JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. *Arterioscler Thromb Vasc Biol.* 2000; 20:1116-22.
9. Kataoka H, Kume N, Miyamoto S, Minami M, Morimoto M, Hayashida K, et al. Oxidized LDL modulates Bax/Bcl-2 through the lectinlike Ox-LDL receptor-1 in vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol.* 2001; 21:955-60.
10. Morrissey PA, Kiely M. Oxysterols: formation and biological function. In: Fox PF, McSweeney PLH (Editors). *Advanced diary chemistry. Lipids.* New York: Springer; 2006. p. 641-674.
11. Colles SM, Maxson JM, Carlson SG, Chisolm GM. Oxidized LDL-induced injury and apoptosis in atherosclerosis. Potential roles for oxysterols. *Trends Cardiovasc Med.* 2001; 11:131-8.
12. Lordan S, Mackrill JJ, O'Brien NM. Oxysterols and mechanisms of apoptotic signaling: implications in the pathology of degenerative diseases. *J Nutr Biochem.* 2009; 20:321-36.
13. Liu J, Thewke DP, Su YR, Linton MF, Fazio S, Sinensky MS. Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low-density lipoprotein receptor-null mice. *Arterioscler Thromb Vasc Biol.* 2005; 25:174-9.
14. Babaev VR, Chew JD, Ding L, Davis S, Breyer MD, Breyer RM, et al. Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis. *Cell Metab.* 2008;8: 492-501.
15. Wang BY, Ho HK, Lin PS, Schwarzscher SP, Pollman MJ, Gibbons GH, et al. Regression of atherosclerosis: role of nitric oxide and apoptosis. *Circulation.* 1999; 99:1236-41.
16. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. *Nat Rev Immunol.* 2010; 10:36-46.
17. Schrijvers DM, De Meyer GR, Kockx MM, Herman AG, Martinet W. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2005; 25:1256-61.
18. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. *Annu Rev Immunol.* 2009; 27:451-83.
19. Viora M, Quaranta MG, Straface E, Vari R, Masella R, Malorni W. Redox imbalance and immune functions: opposite effects of oxidized low-density lipoproteins and N-acetylcysteine. *Immunology.* 2001; 104:431-8.

20. Viora M, Straface E, Di Genova G, Fattorossi A, Rivabene R, Camponeschi B, et al. Oxidized low density lipoproteins impair peripheral blood mononuclear cell proliferation and cytokine production. *Biochem Biophys Res Commun.* 1997; 232:359-63.
21. Hardwick SJ, Hegyi L, Clare K, Law NS, Carpenter KL, Mitchinson MJ, et al. Apoptosis in human monocyte-macrophages exposed to oxidized low density lipoprotein. *J Pathol.* 1996; 179:294-302.
22. Qiu G, Ho AC, Yu W, Hill JS. Suppression of endothelial or lipoprotein lipase in THP-1 macrophages attenuates proinflammatory cytokine secretion. *J Lipid Res.* 2007; 48:385-94.
23. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. *Free Radic Res Commun.* 1989; 6:67-75.
24. Armstrong D, Browne R. The analysis of free radicals, lipid peroxides, antioxidant enzymes and compounds related to oxidative stress as applied to the clinical chemistry laboratory. *Adv Exp Med Biol.* 1994; 366:43-58.
25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods.* 1983; 65:55-63.
26. Lim HK, Kang HK, Yoo ES, Kim BJ, Kim YW, Cho M, et al. Oxysterols induce apoptosis and accumulation of cell cycle at G(2)/M phase in the human monocytic THP-1 cell line. *Life Sci.* 2003; 72:1389-99.
27. Lordan S, O'Callaghan YC, O'Brien NM. Death-signaling pathways in human myeloid cells by oxLDL and its cytotoxic components 7beta-hydroxycholesterol and cholesterol-5beta,6beta-epoxide. *J Biochem Mol Toxicol.* 2007; 21:362-72.
28. Nishio E, Watanabe Y. Oxysterols induced apoptosis in cultured smooth muscle cells through CPP32 protease activation and bcl-2 protein downregulation. *Biochem Biophys Res Commun.* 1996; 226:928-34.
29. Chen J, Mehta JL, Haider N, Zhang X, Narula J, Li D. Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells. *Circ Res.* 2004; 94:370-6.
30. Li HL, Wang AB, Zhang R, Wei YS, Chen HZ, She ZG, et al. A20 inhibits oxidized low-density lipoprotein-induced apoptosis through negative Fas/Fas ligand-dependent activation of caspase-8 and mitochondrial pathways in murine RAW264.7 macrophages. *J Cell Physiol.* 2006; 208:307-18.
31. Verhagen AM, Coulson EJ, Vaux DL. Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. *Genome Biol.* 2001; 2:3009.